Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 4/20 | 0.40 |
| ▸ | DRD2 | P14416 | 3/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.36 |
| ▸ | EBP | Q15125 | 1/20 | 0.36 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.36 |
| ▸ | DRD1 | P21728 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | DRD5 | P21918 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5039661 | 1.00 | HTR1A (0.42) | HTR1ADRD3DRD2OPRM1OPRD1 | |
| SCHEMBL1068540 | 0.89 | CYP3A4 (0.39) | HTR1ADRD3OPRM1OPRK1DRD1 | |
| SCHEMBL5033519 | 0.89 | MEN1 (0.45) | HTR1ADRD3DRD2OPRM1OPRD1 | |
| SCHEMBL8723759 | 0.86 | SIGMAR1 (0.42) | HTR1ADRD3DRD2OPRM1OPRK1 | |
| SCHEMBL2879292 | 0.86 | KCNH2 (0.47) | HTR1ADRD3OPRM1SIGMAR1DRD1 | |
| SCHEMBL9619532 | 0.86 | SIGMAR1 (0.44) | HTR1ADRD3DRD2OPRM1OPRK1 | |
| SCHEMBL10733880 | 0.84 | SIGMAR1 (0.43) | HTR1ADRD3DRD2OPRM1OPRK1 | |
| SCHEMBL5000276 | 0.82 | HTR1A (0.39) | HTR1ADRD3DRD2OPRM1OPRD1 | |
| SCHEMBL16935352 | 0.80 | TDP1 (0.37) | HTR1ADRD3DRD2OPRM1OPRD1 | |
| SCHEMBL23637367 | 0.80 | CARM1 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160326199-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | GIVAUDAN S.A. (CH) | 2016-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160326199-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | PSPH, AS3MT, TST | HTR1A 3926/4885DRD3 2429/4885DRD2 2904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.